International pharmaceutical company GM PHARMA successfully hosted an EU GMP (European Union Good Manufacturing Practice) readiness assessment conducted by representatives of the German consulting company Actrevo GmbH (Hamburg, Germany). The assessment was led by distinguished pharmaceutical industry experts Dr. Harm Peters and Dr. Jens Flemming.

Dr. Harm Peters serves as Chief Executive Officer of Actrevo GmbH and brings extensive international experience in the pharmaceutical sector. Dr. Jens Flemming is the company’s Scientific Director and Qualified Person (QP), with more than 25 years of experience spanning Research and Development (R&D), pharmaceutical manufacturing, regulatory affairs, and Quality Assurance/Quality Control (QA/QC).

During the three-day assessment, the experts observed manufacturing and quality control activities in real time, focusing on a key pharmaceutical product intended for registration in the European market. As with all products manufactured at GM PHARMA, the product under review is produced in accordance with GMP principles and internationally recognized quality standards.

The auditors conducted a comprehensive evaluation of the entire manufacturing process, reviewing each stage from raw material dispensing and weighing through granulation, tableting, coating, packaging, and final product release. Particular attention was given to process controls, documentation practices, product quality assurance, and compliance with EU GMP expectations.

As part of the visit, the experts also performed an extensive review of a strategic product planned for European registration, together with a comprehensive assessment of the company’s manufacturing operations, Quality Control Laboratory, and Microbiological Control Laboratory.

A series of strategic meetings was held with cross-functional teams across the organization, during which participants discussed product development strategies, quality management systems, manufacturing excellence, regulatory requirements and key success factors for operating within highly regulated European pharmaceutical markets.

This important milestone once again demonstrates GM PHARMA’s commitment to the highest international quality standards and reflects the company’s strategic vision of expanding global access to high-quality pharmaceutical products.

GM PHARMA’s manufacturing facility in Tbilisi is one of the leading pharmaceutical production sites in the Caucasus region and operates a fully integrated technological cycle for the manufacturing of solid dosage forms. This end-to-end manufacturing process encompasses every stage, from raw material sourcing and dispensing to wet and dry granulation, tablet coating, primary and secondary packaging, and comprehensive quality control.

Each year, more than 14 million patients benefit from GM PHARMA’s medicines and dietary supplements across Georgia and the company’s international markets. This achievement reflects the strong trust and confidence placed in the company by both healthcare professionals and consumers.

In parallel, GM PHARMA continues to strengthen its research and development capabilities. More than 20 new pharmaceutical products are currently under development within the company’s R&D laboratories. These projects are expected to further expand the company’s portfolio across both domestic and international markets, providing healthcare professionals and patients with innovative therapeutic solutions and improving access to modern treatment options.

Since its foundation, GM PHARMA’s mission and values have remained unchanged: to continuously improve product quality through scientific approaches and industry best practices, and to develop and deliver pharmaceutical products that enhance patients’ quality of life and contribute to longer, healthier lives.

(AD)